SCHEMBL23727664

SCHEMBL23727664

Cc1ccc(-n2ccs/c2=N/C(=O)O)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.45
RAB9A P51151 7/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
ALDH1A1 P00352 4/20 0.45
JAK2 O60674 1/20 0.45
HTT P42858 1/20 0.45
PAX8 Q06710 1/20 0.45
PKM P14618 1/20 0.39
TP53 P04637 1/20 0.36
ALOX5 P09917 1/20 0.36
PTGS2 P35354 1/20 0.36
LMNA P02545 1/20 0.35
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
CASP3 P42574 1/20 0.34
SENP7 Q9BQF6 1/20 0.34
SENP6 Q9GZR1 1/20 0.34
RECQL P46063 1/20 0.33
NOTUM Q6P988 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23727665 1.00 NPC1 (0.45) NPC1RAB9ASMN1; SMN2ALDH1A1JAK2
SCHEMBL23727586 0.85 NPC1 (0.43) NPC1RAB9ASMN1; SMN2ALDH1A1JAK2
SCHEMBL23727585 0.85 NPC1 (0.43) NPC1RAB9ASMN1; SMN2ALDH1A1JAK2
SCHEMBL23727748 0.84 PKM (0.38) NPC1RAB9ASMN1; SMN2ALDH1A1JAK2
SCHEMBL23727796 0.84 NPC1 (0.48) NPC1RAB9ASMN1; SMN2ALDH1A1JAK2
SCHEMBL23727797 0.84 NPC1 (0.48) NPC1RAB9ASMN1; SMN2ALDH1A1JAK2
SCHEMBL23727749 0.84 PKM (0.38) NPC1RAB9ASMN1; SMN2ALDH1A1JAK2
SCHEMBL23727946 0.84 NPC1 (0.52) NPC1RAB9ASMN1; SMN2ALDH1A1HTT
SCHEMBL23727949 0.84 NPC1 (0.52) NPC1RAB9ASMN1; SMN2ALDH1A1HTT
SCHEMBL23727904 0.82 NOTUM (0.40) NPC1RAB9ASMN1; SMN2ALDH1A1JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230137893-A1 PYRROLO[2,3-b]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS THE ROCKEFELLER UNIVERSITY (US) 2023-05-04 US disclosed
EP-4100008-A1 PYRROLO [2,3-B]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS The Rockefeller University (US) 2022-12-14 EP disclosed
WO-2021158936-A1 PYRROLO [2,3-B]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS THE ROCKEFELLER UNIVERSITY (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230137893-A1 PYRROLO[2,3-b]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS LATS2, LATS1, YAP1 NPC1 3977/4885RAB9A 2076/4885SMN1; SMN2 2796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.